A HUB OF EXCELLENCE IN LIFE SCIENCES

RESEARCH AREA

INAB|CERTH is at the forefront of research across all domains in Life Sciences

PILLARS

Bioanalysis, Real world evidence, Implementation science

ΜISSION

To address the gap between research excellence in Life Sciences and applications that meet end-user demands

INAB
NEWS

Το ΙΝΕΒ ενισχύει τις συμμαχίες για τη βιώσιμη ανά…

Την ανάπτυξη κοινών ερευνητικών δράσεων που βασίζονται στην ανάλυση αστικών λυμ…

IC-GROWTH: Ερευνητικό πρόγραμμα για την υποστήριξ…

Η Ψυχοκοινωνική Υποστήριξη μετά την Ογκολογική Θεραπεία και η Μετατραυματική Αν…

Placeholder

Εκστρατεία Ενημέρωσης για τον HPV από το ΙΝΕΒ/ ΕΚ…

Μια νέα ενημερωτική πρωτοβουλία για την πρόληψη του ιού των ανθρωπίνων θηλωμάτω…

Placeholder

«Ψυχοκοινωνική Υποστήριξη μετά την Ογκολογική Θερ…

Το Εργαστήριο Ψυχολογίας του Ινστιτούτου Εφαρμοσμένων Βιοεπιστημών (ΙΝΕΒ) του Ε…

Ο Πρόεδρος του Δ.Σ. της ΗΔΙΚΑ Α.Ε., Ιωάννης Καραγ…

Το Ινστιτούτο Εφαρμοσμένων Βιοεπιστημών (ΙΝΕΒ) του Εθνικού Κέντρου Έρευνας και …

Με νέες λύσεις το ΙΝΕΒ/ ΕΚΕΤΑ στην 89η ΔΕΘ Alzhe…

Το Ινστιτούτο Εφαρμοσμένων Βιοεπιστημών του ΕΚΕΤΑ είχε την ευκαιρία κατά τη διά…

Placeholder

Το ΙΝΕΒ/ ΕΚΕΤΑ στον ΟΟΣΑ

«Πρόσβαση στο Ερευνητικό Λογισμικό: Ευκαιρίες και Προκλήσεις» ήταν το θέμα της …

Το ΙΝΕΒ/ ΕΚΕΤΑ στην 89η ΔΕΘ

Με ερευνητικές δράσεις που έχουν άμεσο αντίκτυπο στην κοινωνία, το Ινστιτούτο Ε…

Placeholder

Το ΙΝΕΒ/ ΕΚΕΤΑ Εθνικός Κόμβος Δεδομένων για τον Κ…

Η Ελλάδα συμμετέχει ενεργά, μέσω του Ινστιτούτου Εφαρμοσμένων Βιοεπιστημών (ΙΝΕ…

INAB
ONE HEALTH

INAB
INSTITUTE OF
APPLIED BIOSCIENCES

The Institute of Applied Biosciences at the Centre for Research and Technology Hellas, INAB|CERTH, conducts research in the Life Sciences that extends from microbes to plants,
animals and humans. Our aim at INAB is to promote basic research, while providing solutions to
important social needs related to health and well-being. In this context, INAB conducts Biomedical research and deals with the development and evaluation of digital health
interventions and personalized medicine, while also holding a leading position in Agri-biotechnology, utilizing modern high-performance methodologies, molecular 
biotechnology and ‘breeding by design’ approaches, with the aim of developing high quality and value products. We work towards this direction with the basic principle of cooperation between scientists with different but complementary knowledge and skills. The main pillars of our
activity are bioanalysis, real world data and the development of relevant applications.

The Institute of Applied Biosciences at the Centre for Research and Technology Hellas, INAB|CERTH, conducts research in the Life Sciences that extends from microbes to plants, animals and humans. Our aim at INAB is to promote basic research, while providing solutions to important social needs related to health and well-being. In this context, INAB conducts Biomedical research and deals with the development and evaluation of digital health interventions and personalized medicine, while also holding a leading position in Agri-biotechnology, utilizing modern high-performance methodologies, molecular biotechnology and ‘breeding by design’ approaches, with the aim of developing high quality and value products. We work towards this direction with the basic principle of cooperation between scientists with different but complementary knowledge and skills. The main pillars of our activity are bioanalysis, real world data and the development of relevant applications.

we rely
on knowledge & cooperation

we innovate
in the Life Sciences

we respond
to social needs

INAB
Certifications

The vision of ΙΝΑΒ is to maintain the highest possible level of quality in the entire spectrum of its operations and services.

INAB has established a robust Integrated Information Security (IS) and Business Continuity (BC) Management System, certified according to ISO/IEC 27001:2013 and ISO 22301:2019 respectively. This system, diligently maintained since 2018, underscores INAB’s commitment to security, data protection and operational resilience.

INΑB has installed and implements a Quality Management System according to the ELOT EN ISO/IEC 15189:2012 Standard, the relevant documents of ESYD, as well as any other specifications related to the activities of the Laboratories. ΙΝΑΒ is committed to complying with the requirements of the above Standard and continuously improving its efficiency. The system is maintained since 2018.

The laboratories participate in external quality control schemes and are constantly updating their certificates as well as enriching their fields of accreditation with new ones. You can see here, the Institute’s “Table of Participation in external quality assessment schemes”.

PARTICIPATION IN EXTERNAL QUALITY
ASSESSMENT SCHEMES

Detection of TP53 gene mutations (Sanger Sequencing)

ORGANIZATION

Instand e.V

SCHEME

Molecular Oncology TP53

Detection of TP53 gene mutations by next-generation sequencing

ORGANIZATION

GenQA-ERIC

SCHEME

TP53 Certification

Determination of T cell receptor β chain gene rearrangements

ORGANIZATION

UK NEQAS

SCHEME

TCR Clonality Status

Determination of immunoglobulin heavy chain gene rearrangements

ORGANIZATION

UK NEQAS

SCHEME

IgH Clonality Status

Molecular detection of the SARS-CoV-2 virus

ORGANIZATION

EMQN_ QCMD Quality Control for Molecular Diagnostics

SCHEME

SARS-CoV-2 EQA Programme

Detection of mutations in hematologic malignancies

ORGANIZATION

EMQN_ QCMD Quality Control for Molecular Diagnostics

SCHEME

ONCOGENE_PANEL-22

Determination of IGHV gene somatic hypermutation status

ORGANIZATION

UK NEQAS

SCHEME

Chronic Lymphocytic Leukaemia (CLL) IGHV mutation status_GenQA

Detection of mutations in solid tumors

ORGANIZATION

EMQN_ QCMD Quality Control for Molecular Diagnostics

SCHEME

ONCOGENE_PANEL-22

Detection of TP53 gene mutations by next-generation sequencing

ORGANIZATION

ERIC, European Research Initiative on CLL

SCHEME

TP53 Certification

Determination of IGHV gene somatic hypermutation status

ORGANIZATION

ERIC, European Research Initiative on CLL

SCHEME

Chronic Lymphocytic Leukemia (CLL) IGHV mutation status